A Novel COX-2 Inhibitor Pyrazole Derivative Proven Effective as an Anti-Inflammatory and Analgesic Drug

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 4, 2011, Pages 263-273

  Mohy El Din, Mahmoud M ^a   Senbel, Amira M ^a   Bistawroos, Azza A ^a   El Mallah, Ahmed ^a   Nour El Din, Nour A ^a   Bekhit, Adnan A ^a   Abd El Razik, Heba A ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 SULFAMOYLPHENYL) 3 (4 METHYLPHENYL) 1H PYRAZOLE 4 CARBOXYLIC ACID; 4 (3 PHENYL 4 CYANO 1H PYRAZOL 1 YL)BENZENESULFONAMIDE; 4 [3 (4 BROMOPHENYL) 4 CYANO 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 (4 CHLOROPHENYL) 4 CYANO 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 (4 METHYLPHENYL) 4 (3 PHENYL 4 OXOTHIAZOLIDIN 2 YLIDENEHYDRAZONOMETHYL) 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 (4 METHYLPHENYL) 4 [4 (4 BROMOPHENYL) 3 (4 CHLOROPHENYL) 2,3 DIHYDROTHIAZOL 2 YLIDENEHYDRAZONOMETHYL] 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 (4 METHYLPHENYL) 4 [4 (4 BROMOPHENYL) 3 (4-METHYLPHENYL) 2,3 DIHYDROTHIAZOL 2 YLIDENEHYDRAZONOMETHYL] 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 (4 METHYLPHENYL) 4 [4 (4 BROMOPHENYL) 3 PHENYL 2,3 DIHYDROTHIAZOL 2 YLIDENEHYDRAZONOMETHYL] 1H PYRAZOL 1 YL] BENZENESULFONAMIDE; 4 [3 (4 METHYLPHENYL) 4 CYANO 1H PYRAZOL 1 YL)BENZENESULFONAMIDE; 4 [3 (4 METHYLPHENYL) 4 CYANO 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 (4 NITROPHENYL) 4 CYANO 1H PYRAZOL 1 YL)BENZENESULFONAMIDE; 4 [3 [4 METHYLPHENYL 4 [3 (4 METHYLPHENYL) 2 OXOPROPEN 1 YL] 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; AD 531; AD 532; AD 533; AD 534; AD 535; AD 539 CH; AD 542 CH; AD 543 CH; AD 544 CH; AD 558; AD 565; AD 566; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FORMALDEHYDE; INDOMETACIN; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOTOXICITY; DRUG EFFICACY; FEMALE; HOT PLATE TEST; HYPERALGESIA; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; CHRONIC DISEASE; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; EDEMA; FEMALE; FORMALDEHYDE; HYPERALGESIA; INDOMETHACIN; INFLAMMATION; MALE; MICE; PYRAZOLES; RATS; SULFONAMIDES; ULCER;

GOSSYPIUM HIRSUTUM;

EID: 79952786277     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00648.x     Document Type: Article

References (60)

1. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr 2008;19(2):102-7.
2. Vane JR, Botting RM. Mechanism of action of nonsteroidal antiinflammatory drugs. Am J Med 1998;104(3A):2S-8S.
3. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte L et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
4. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998;87(2):319-24.
5. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24(1):83-7.
6. Burke A, Smyth EM, FitzGerald GA. Analgesic-antipyretic agents; pharmacotherapy of Gout. In: Hardman JG, Limbird LE (eds). Goodman & Gilman's. The pharmacological basis of therapeutics, 11th edn. Pub. McGraw-Hill, Inc., New York, 2006; 671-716.
7. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12(11):1-178.
8. Dilger K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 2002;42(9):985-94.
9. Day R. Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 2002;29(8):1581-2.
10. Jia JM, Wu CF, Liu W, Yu H, Hao Y, Zheng JH et al. Antiinflammatory and analgesic activities of the tissue culture of Saussurea involucrate. Biol Pharm Bull 2005;28(9):1612-4.
11. Gupta M, Mazumdar UK, Sivakumar T, Vamsi ML, Karki SS, Sambathkumar R et al. Evaluation of anti-inflammatory activity of chloroform extract of Bryonia laciniosa in experimental animal models. Biol Pharm Bull 2003;26(9):1342-4.
12. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987; 30(1):103-14.
13. Lu Z, Xiong X, Zhang B, Lin G, Shi Y, Liu Z et al. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1. Acta Pharmacol Sin 2005;26(12):1505-11.
14. Wakitani K, Nanayama T, Masaki M, Matsushita M. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor. Jpn J Pharmacol 1998;78(3):365-71.
15. Harirforoosh S, Jamali F. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat. Can J Physiol Pharmacol 2005;83(1):85-90.
16. Fawcett JK, Scott JE. A rapid and precise method for the determination of urea. J clin Pathol 1960;13:156-9.
17. Lustgarten JA, Wenk RE. Simple, rapid, kinetic method for serum creatinine measurement. Clin Chem 1972;18(11):1419-22.
18. Lubran MM. The measurement of total serum proteins by the Biuret method. Ann Clin Lab Sci 1978;8(2):106-10.
19. Amadio PJr, Cummings DM, Amadio P. Nonsteroidal anti-inflammatory drugs. Tailoring therapy to achieve results and avoid toxicity. Postgrad Med 1993;93(4):73-97.
20. Suleyman H, Buyukokuroglu ME. The effects of newly synthesized pyrazole derivatives on Formaldehyde-, Carrageenan-, and dextran-induced acute paw edema in rats. Biol Pharm Bull 2001;24(10):1133-6.
21. Ogata M, Matsui T, Kita T, Shigematsu A. Carrageenan primes leukocytes to enhance lipopolysaccharide-induced tumor necrosis factor alpha production. Infect Immun 1999;67(7):3284-9.
22. Nacife VP, Soeiro Mde N, Gomes RN, D'Avila H, Castro-Faria Neto HC, Meirelles Mde N. Morphological and biochemical characterization of macrophages activated by carrageenan and lipopolysaccharide in-vivo. Cell Struct Funct 2004;29(2):27-34.
23. Autore G, Marzocco S, Sorrentino R, Mirone VG, Baydoun A, Pinto A. In vitro and in vivo TNFalpha synthesis modulation by methylguanidine, an uremic catabolyte. Life Sci 1999;65(11):121-7.
24. Ohira H, Ueno T, Torimura T, Tanikawa K, Kasukawa R. Leukocyte adhesion molecules in the liver and plasma cytokine levels in endotoxin-induced rat liver injury. Scand J Gastroenterol 1995;30(10):1027-35.
25. Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 1993;54(2):171-8.
26. Bekhit AA, Fahmy HT, Rostom SA, Baraka AM. Design and synthesis of some substituted 1H-pyrazolyl-thiazolo[4, 5-d]pyrimidines as anti-inflammatory antimicrobial agents. Eur J Med Chem 2003;38(1):27-36.
27. Bekhit AA, Abdel-Azeim T. Design, synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatory-antimicrobial agents. Bioorg Med Chem 2004;12(8):1935-45.
28. Li M, Yin L, Cai M, Zhang W, Huang Y, Wang X et al. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1, 5-diarylpyrazole derivatives. Acta Pharmacol Sin 2005;26(7):865-72.
29. Bekhit AA, Abdel-Rahman HM, Guemei AA. Synthesis and biological evaluation of some hydroxypyrazole derivatives as anti-inflammatory-antimicrobial agents. Arch Pharm (Weinheim) 2006;339(2):81-7.
30. Trongsakul S, Panthong A, Kanjanapothi D, Taesotikul T. The analgesic, antipyretic and anti-inflammatory activity of Diospyros variegata Kruz. J Ethnopharmacol 2003;3:221-5.
31. Franca DS, Souza AL, Almeida KR, Dolabella SS, Martinelli C, Coelho MM. B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice. Eur J Pharmacol 2001;421(3):157-64.
32. Campos AR, Albuquerque FA, Rao VS, Maciel MA, Pinto AC. Investigations on the antinociceptive activity of crude extracts from Croton cajucara leaves in mice. Fitoterapia 2002;73(2):116-20.
33. Dai Y, Ye WC, Wang ZT, Matsuda H, Kubo M, But PP. Antipruritic and antinociceptive effects of Chenopodium album L in mice. J Ethnopharmacol 2002;81(2):245-50.
34. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992;51(1):5-17.
35. Santos AR, Gadotti VM, Oliveira GL, Tibola D, Paszcuk AF, Neto A et al. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology 2005;48(7):1021-34.
36. Shibata M, Ohkubo T, Takahashi H, Inoki R. Modified formalin test: characteristic biphasic pain response. Pain 1989;38(3):347-52.
37. Yaksh TL. Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol Sci 1999;20(8):329-37.
38. Rosland JH, Tjolsen A, Maehle B, Hole K. The formalin test in mice: effect of formalin concentration. Pain 1990;42(2):235-42.
39. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001;53(4):597-652.
40. Yamamoto T, Nozaki-Taguchi N. The role of Cyclooxygenase-1 and -2 in the rat formalin test. Anesth Analg 2002;94:962-7.
41. Ballou LR, Botting RM, Goorha S, Zhang J, Vane JR. Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci USA 2000;97(18):10272-6.
42. Viegas C Jr, Alexandre-Moreira MS, Fraga CA, Barreiro EJ, Bolzani Vda S, de Miranda AL. Antinociceptive Profile of 2, 3, 6-Trisubstituted Piperidine Alkaloids: 3-O-Acetyl-spectaline and Semi-synthetic Derivatives of Spectaline. Chem Pharm Bull 2008; 56(4):407-12.
43. Choi J, Jung B, Kang O, Choi HJ, Park PS, Cho SH et al. The anti-inflammatory and anti-nociceptive effects of ethyl acetate fraction of cynanchi paniculati radix. Biol Pharm Bull 2006; 29(5):971-5.
44. Hasinoff BB, Patel D, Wu X. The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovasc Toxicol 2007;7(1):19-27.
45. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C et al. Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol 2008;76(7):862-72.
46. Tsutsumi R, Ito H, Hiramitsu T, Nishitani K, Akiyoshi M, Kitaori T et al. Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes. Rheumatol Int 2008;28(8):727-36.
47. Pyrko P, Kardosh A, Schonthal AH. Celecoxib transiently inhibits cellular protein synthesis. Biochem Pharmacol 2008;75(2):395-404.
48. Salzberg DJ, Weir MR. COX-2 inhibitors and cardiovascular risk. Subcell Biochem 2007;42:159-74.
49. Capone ML, Tacconelli S, Francesco LD, Petrelli M, Patrignani P. Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. Expert Opin Drug Saf 2008;7(1):29-42.
50. Sciulli MG, Capone ML, Tacconelli S, Patrignani P. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 2005;57:66-85.
51. Ferguson S, Hebert RL, Laneuville O. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J Am Soc Nephrol 1999;10(11):2261-71.
52. Khan KN, Paulson SK, Verburg KM, Lefkowith JB, Maziasz TJ. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 2002;61:1210-9.
53. Cortan RS, Kumar V, Collins T. Cellular pathology I: Cell injury and cell death. In: Cortan RS, Kumar V, Collins T (eds). Robbins Pathological basis of disease, 6th edn. Pub. W.B. Saunders Co., Philadelphia, 1999; 1-30.
54. Schnellmann RG. Toxic responses of the kidney. In: Klaassen CD.(ed.) Casarett and Doull's toxicology: The basic science of poisons, 6th edn. Pub. McGraw-Hill Co., New York, 2001; 491-514.
55. Perez M, Castilla M, Torres AM, Lazaro JA, Sarmiento E, Tejedor A. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Nephrol Dial Transplant 2004;19(10):2445-55.
56. Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions. JAMA 1978;240(19): 2067-9.
57. Forbes GB. Sodium. In: Comar CL, Bronner F (eds). Mineral metabolism. Volume II: The elements. Pub. Academic press, New York and London, 1962; 2-72.
58. Battarbee HD, Grisham MB, Johnson GG, Zavecz JH. Superior mesenteric artery blood flow and indomethacin-induced intestinal injury and inflammation. Am J Physiol 1996;1:G605-12.
59. Kirchner T, Aparicio B, Argentieri DC, Lau CY, Ritchie DM. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 1997; 56(6):417-23.
60. Wallace JL, Bak A, Mcknight W, Asfaha S, Sharkey KA, Macnaughton WK. Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: implications for Gastrointestinal Toxicity. Gastroenterology 1998;115:101-9.